Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00282113 · ClinicalTrials.gov registry record · NA
Effects of Probiotic and Prebiotic Combinations on Premature Infants
A NA study, sponsored by University of California, Davis.
- Completed
- Registry status
- NA
- Development phase
- 90
- Enrollment target
NCT00282113: Completed NA study, sponsored by University of California, Davis.
NCT00282113 is a NA study that has completed, run by University of California, Davis. The registered enrollment target is 90 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00282113, a NA study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
Study Summary
The purpose of this study is to see how oral preparations containing both probiotics and prebiotics impact the growth, bacterial colonization of the intestines, and fecal short chain fatty acid content in premature infants. Our hypothesis is that short term growth will be improved, the stool will have more healthy bacteria, and the fecal short chain fatty acid content will increase in the babies who receive the probiotic/prebiotic combinations compared to control groups.
Primary Outcome
Weight at five weeks minus birth weight
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT ProBioPlus
- DIETARY_SUPPLEMENT Culturelle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2004-10 |
| Est. Completion | 2007-08 |
| Phase | NA |
What the finished NCT00282113 record still lists
NCT00282113 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00282113 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00282113 about?
NCT00282113 is a clinical study titled "Effects of Probiotic and Prebiotic Combinations on Premature Infants". The purpose of this study is to see how oral preparations containing both probiotics and prebiotics impact the growth, bacterial colonization of the intestines, and fecal short chain fatty acid content in premature infants. Our hypothesis is that short term growth will be improved, the stool will ha...
What is the current status of trial NCT00282113?
This trial is currently completed. It is a NA study. The enrollment target is 90 participants. The study started on 2004-10. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00282113?
The interventions under investigation include: Placebo (OTHER), ProBioPlus (DIETARY_SUPPLEMENT), Culturelle (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00282113?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00282113's enrollment target sits among peer trials
90 941st of 2000 higher than 1,029 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia